MK-8353
- Generic Name
- MK-8353
Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT03745989
- Locations
- 🇺🇸
Florida Cancer Specialists ( Site 7000), Sarasota, Florida, United States
🇺🇸Next Oncology ( Site 0001), San Antonio, Texas, United States
🇨🇦Princess Margaret Cancer Centre ( Site 0012), Toronto, Ontario, Canada
Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
Phase 1
Terminated
- Conditions
- NeoplasmsColorectal Cancer
- Interventions
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 111
- Registration Number
- NCT02972034
- Locations
- 🇨🇦
Merck Canada, Kirkland, Quebec, Canada
🇺🇸Call for Information (Investigational Site 0002), Grand Rapids, Michigan, United States
🇺🇸Call for Information (Investigational Site 0001), Nashville, Tennessee, United States
A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 25
- Registration Number
- NCT01358331
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath